Company: OSRH
Filing Date: 2025-05-28
Form Type: S-1
Source: 0001213900-25-048346
Chunk: 80

Company: OSR Holdings, Inc.
Filing Date: 2025-05-28
Form: S-1
Chunk 80
---
otes chondrogenesis in damaged cartilage tissue by signaling primarily via the type II receptor BMPRII and to a lesser extent via
the activin type II receptor ActRII, which it binds with lower affinity. DRT-101 amplifies intracellular regeneration signaling capacity
compared to natural BMP-7 and allows for regeneration and restoration of mechanically depleted cartilage cells to normal levels.

Osteoarthritis is the most common joint
disorder in the aging population. Although surgical treatment of osteoar-thritis can reduce pain and improve joint mobility and function,
the operative management of osteoarthritis is associated with significant cost and morbidity. Unmet medical needs for DRT-101 for Osteoarthritis
are enormous specially with aging population. Unique market opportunity of DRT-101 relies on novel Mechanism of Action of DRT-101 that
can lead to potential first-in-class DMOAD (Disease-Modifying Osteoarthritis Drug) in the market.

Darnatein is pursuing pre-clinical studies
of DRT-101 targeting osteoarthritis and plans to file Investigational New Drug Application (IND) to the U.S. Food and Drug Administration
by 2025 for Phase 1 clinical trial, with aims of FDA approval by 2032. Darnatein will seek to create cashflow via licensing deals from
the preclinical and clinical developments of its pipeline assets.

Net cashflow from the acquisitions for
the three months ended March 31, 2025 and 2024 are as follows:

| Net cash outflow arising from acquisition of Darnatein: |     |   | 2025 |
|:--------------------------------------------------------|:----|:--|:-----|
| Cash consideration                                      |     | $ | -    |
| Less: cash and cash equivalent balances acquired        |     |   | -    |
|                                                         |     | $ | -    |

| Net cash outflow arising from acquisition of VAXIMM and RMC: |     |   | 2024 |
|:-------------------------------------------------------------|:----|:--|:-----|
| Cash consideration                                           |     | $ | -    |
| Less: cash and cash equivalent balances acquired             |     |   | -    |
|                                                              |     | $ | -    |

| (24) | Commitment        
 and contingencies |

The Group has no pending litigation
cases arising in the ordinary course of business as of March